The Role & Implementation of AAV Immunogenicity Assays in Gene Therapy Clinical Trials

• Importance of detecting pre-existing AAV antibodies to ensure safety and efficacy in gene therapy trials
• Determination of thresholds for AAV immunogenicity assays through pre-clinical and clinical studies
• Implementation of validated AAV cut-offs in patient selection strategies

Speakers:

Melis McHenry

Associate Director

Regeneron Pharmaceuticals